APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Oral Anticoagulants (DOACs)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Direct Oral Anticoagulants (DOACs) Market Analysis and Forecast 2026-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchDirect Oral Anticoagulants (DOACs) Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Oral Anticoagulants (DOACs) Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Direct Oral Anticoagulants (DOACs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Oral Anticoagulants (DOACs) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Oral Anticoagulants (DOACs) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Direct Oral Anticoagulants (DOACs) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Direct Oral Anticoagulants (DOACs) include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Direct Oral Anticoagulants (DOACs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Direct Oral Anticoagulants (DOACs), also provides the sales of main regions and countries. Of the upcoming market potential for Direct Oral Anticoagulants (DOACs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Direct Oral Anticoagulants (DOACs) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Direct Oral Anticoagulants (DOACs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Direct Oral Anticoagulants (DOACs) sales, projected growth trends, production technology, application and end-user industry.

Direct Oral Anticoagulants (DOACs) Segment by Company

Accord Healthcare

Apotex

Boehringer Ingelheim

Bristol Myers Squibb

Daiichi Sankyo

GlaxoSmithKline

Janssen Pharmaceuticals

Teva Pharmaceutical

Viatris

Bayer

Pfizer

Mylan

Sandoz

Direct Oral Anticoagulants (DOACs) Segment by Type

Oral Factor Xa Inhibitors

Direct Thrombin Inhibitors (DTIs)

Direct Oral Anticoagulants (DOACs) Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Direct Oral Anticoagulants (DOACs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Direct Oral Anticoagulants (DOACs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Direct Oral Anticoagulants (DOACs) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Direct Oral Anticoagulants (DOACs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Factor Xa Inhibitors Major Manufacturers Table 3. Direct Thrombin Inhibitors (DTIs) Major Manufacturers Table 4. Global Direct Oral Anticoagulants (DOACs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pulmonary Embolism Major Manufacturers Table 6. Deep Vein Thrombosis Major Manufacturers Table 7. Atrial Fibrillation Major Manufacturers Table 8. Other Major Manufacturers Table 9. Direct Oral Anticoagulants (DOACs) Industry Trends Table 10. Direct Oral Anticoagulants (DOACs) Industry Drivers Table 11. Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges Table 12. Direct Oral Anticoagulants (DOACs) Industry Restraints Table 13. Global Direct Oral Anticoagulants (DOACs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2026) Table 17. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2027-2032) Table 18. Global Direct Oral Anticoagulants (DOACs) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (K Units) Table 20. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2027-2032) & (K Units) Table 21. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2026) Table 22. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2027-2032) Table 23. Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2021-2026) Table 27. Global Direct Oral Anticoagulants (DOACs) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Direct Oral Anticoagulants (DOACs) Manufacturers, Product Type & Application Table 31. Global Direct Oral Anticoagulants (DOACs) Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Direct Oral Anticoagulants (DOACs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Direct Oral Anticoagulants (DOACs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2026) Table 38. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2027-2032) Table 39. Global Direct Oral Anticoagulants (DOACs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 41. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 42. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026) Table 43. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2027-2032) Table 44. Global Direct Oral Anticoagulants (DOACs) Price by Type (2021-2026) & (US$/Unit) Table 45. Global Direct Oral Anticoagulants (DOACs) Price by Type (2027-2032) & (US$/Unit) Table 46. Global Direct Oral Anticoagulants (DOACs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2026) Table 50. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2027-2032) Table 51. Global Direct Oral Anticoagulants (DOACs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 53. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 54. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026) Table 55. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2027-2032) Table 56. Global Direct Oral Anticoagulants (DOACs) Price by Application (2021-2026) & (US$/Unit) Table 57. Global Direct Oral Anticoagulants (DOACs) Price by Application (2027-2032) & (US$/Unit) Table 58. Accord Healthcare Company Information Table 59. Accord Healthcare Business Overview Table 60. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio Table 62. Accord Healthcare Recent Development Table 63. Apotex Company Information Table 64. Apotex Business Overview Table 65. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio Table 67. Apotex Recent Development Table 68. Boehringer Ingelheim Company Information Table 69. Boehringer Ingelheim Business Overview Table 70. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio Table 72. Boehringer Ingelheim Recent Development Table 73. Bristol Myers Squibb Company Information Table 74. Bristol Myers Squibb Business Overview Table 75. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio Table 77. Bristol Myers Squibb Recent Development Table 78. Daiichi Sankyo Company Information Table 79. Daiichi Sankyo Business Overview Table 80. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio Table 82. Daiichi Sankyo Recent Development Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio Table 87. GlaxoSmithKline Recent Development Table 88. Janssen Pharmaceuticals Company Information Table 89. Janssen Pharmaceuticals Business Overview Table 90. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio Table 92. Janssen Pharmaceuticals Recent Development Table 93. Teva Pharmaceutical Company Information Table 94. Teva Pharmaceutical Business Overview Table 95. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio Table 97. Teva Pharmaceutical Recent Development Table 98. Viatris Company Information Table 99. Viatris Business Overview Table 100. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio Table 102. Viatris Recent Development Table 103. Bayer Company Information Table 104. Bayer Business Overview Table 105. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 107. Bayer Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 112. Pfizer Recent Development Table 113. Mylan Company Information Table 114. Mylan Business Overview Table 115. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio Table 117. Mylan Recent Development Table 118. Sandoz Company Information Table 119. Sandoz Business Overview Table 120. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio Table 122. Sandoz Recent Development Table 123. North America Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (US$ Million) Table 124. North America Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (US$ Million) Table 125. North America Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 126. North America Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 127. North America Direct Oral Anticoagulants (DOACs) Sales Price by Type (2021-2026) & (US$/Unit) Table 128. North America Direct Oral Anticoagulants (DOACs) Sales Price by Type (2027-2032) & (US$/Unit) Table 129. North America Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 132. North America Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 133. North America Direct Oral Anticoagulants (DOACs) Sales Price by Application (2021-2026) & (US$/Unit) Table 134. North America Direct Oral Anticoagulants (DOACs) Sales Price by Application (2027-2032) & (US$/Unit) Table 135. North America Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. North America Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 137. North America Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 138. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 139. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 140. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 141. North America Direct Oral Anticoagulants (DOACs) Sales Price by Country (2021-2026) & (US$/Unit) Table 142. North America Direct Oral Anticoagulants (DOACs) Sales Price by Country (2027-2032) & (US$/Unit) Table 143. United States Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 144. Canada Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 145. Mexico Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 146. Europe Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (US$ Million) Table 147. Europe Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (US$ Million) Table 148. Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 149. Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 150. Europe Direct Oral Anticoagulants (DOACs) Sales Price by Type (2021-2026) & (US$/Unit) Table 151. Europe Direct Oral Anticoagulants (DOACs) Sales Price by Type (2027-2032) & (US$/Unit) Table 152. Europe Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (US$ Million) Table 153. Europe Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (US$ Million) Table 154. Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 155. Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 156. Europe Direct Oral Anticoagulants (DOACs) Sales Price by Application (2021-2026) & (US$/Unit) Table 157. Europe Direct Oral Anticoagulants (DOACs) Sales Price by Application (2027-2032) & (US$/Unit) Table 158. Europe Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Europe Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. Europe Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 162. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 163. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 164. Europe Direct Oral Anticoagulants (DOACs) Sales Price by Country (2021-2026) & (US$/Unit) Table 165. Europe Direct Oral Anticoagulants (DOACs) Sales Price by Country (2027-2032) & (US$/Unit) Table 166. Germany Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 167. France Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 168. U.K. Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 169. Italy Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 170. Russia Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 171. Spain Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 172. Netherlands Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 173. Switzerland Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 174. Sweden Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 175. Poland Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 176. China Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (US$ Million) Table 177. China Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (US$ Million) Table 178. China Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 179. China Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 180. China Direct Oral Anticoagulants (DOACs) Sales Price by Type (2021-2026) & (US$/Unit) Table 181. China Direct Oral Anticoagulants (DOACs) Sales Price by Type (2027-2032) & (US$/Unit) Table 182. China Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (US$ Million) Table 183. China Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (US$ Million) Table 184. China Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 185. China Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 186. China Direct Oral Anticoagulants (DOACs) Sales Price by Application (2021-2026) & (US$/Unit) Table 187. China Direct Oral Anticoagulants (DOACs) Sales Price by Application (2027-2032) & (US$/Unit) Table 188. Asia Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (US$ Million) Table 189. Asia Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (US$ Million) Table 190. Asia Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 191. Asia Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 192. Asia Direct Oral Anticoagulants (DOACs) Sales Price by Type (2021-2026) & (US$/Unit) Table 193. Asia Direct Oral Anticoagulants (DOACs) Sales Price by Type (2027-2032) & (US$/Unit) Table 194. Asia Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (US$ Million) Table 195. Asia Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (US$ Million) Table 196. Asia Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 197. Asia Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 198. Asia Direct Oral Anticoagulants (DOACs) Sales Price by Application (2021-2026) & (US$/Unit) Table 199. Asia Direct Oral Anticoagulants (DOACs) Sales Price by Application (2027-2032) & (US$/Unit) Table 200. Asia Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 201. Asia Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 202. Asia Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 203. Asia Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 204. Asia Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 205. Asia Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 206. Asia Direct Oral Anticoagulants (DOACs) Sales Price by Country (2021-2026) & (US$/Unit) Table 207. Asia Direct Oral Anticoagulants (DOACs) Sales Price by Country (2027-2032) & (US$/Unit) Table 208. Japan Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 209. South Korea Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 210. India Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 211. Australia Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 212. Taiwan Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 213. Southeast Asia Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 214. SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & (US$ Million) Table 215. SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Type (2027-2032) & (US$ Million) Table 216. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 217. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 218. SAMEA Direct Oral Anticoagulants (DOACs) Sales Price by Type (2021-2026) & (US$/Unit) Table 219. SAMEA Direct Oral Anticoagulants (DOACs) Sales Price by Type (2027-2032) & (US$/Unit) Table 220. SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & (US$ Million) Table 221. SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Application (2027-2032) & (US$ Million) Table 222. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 223. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 224. SAMEA Direct Oral Anticoagulants (DOACs) Sales Price by Application (2021-2026) & (US$/Unit) Table 225. SAMEA Direct Oral Anticoagulants (DOACs) Sales Price by Application (2027-2032) & (US$/Unit) Table 226. SAMEA Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. SAMEA Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. SAMEA Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 230. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 231. SAMEA Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 232. SAMEA Direct Oral Anticoagulants (DOACs) Sales Price by Country (2021-2026) & (US$/Unit) Table 233. SAMEA Direct Oral Anticoagulants (DOACs) Sales Price by Country (2027-2032) & (US$/Unit) Table 234. Brazil Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 235. Argentina Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 236. Chile Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 237. Colombia Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 238. Peru Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 239. Saudi Arabia Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 240. Israel Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 241. UAE Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 242. Turkey Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 243. Iran Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 244. Egypt Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Table 245. Key Raw Materials Table 246. Raw Materials Key Suppliers Table 247. Direct Oral Anticoagulants (DOACs) Distributors List Table 248. Direct Oral Anticoagulants (DOACs) Customers List Table 249. Research Programs/Design for This Report Table 250. Authors List of This Report Table 251. Secondary Sources Table 252. Primary Sources List of Figures Figure 1. Direct Oral Anticoagulants (DOACs) Image Figure 2. Global Direct Oral Anticoagulants (DOACs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Oral Anticoagulants (DOACs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Factor Xa Inhibitors Image Figure 5. Direct Thrombin Inhibitors (DTIs) Image Figure 6. Global Direct Oral Anticoagulants (DOACs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Direct Oral Anticoagulants (DOACs) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pulmonary Embolism Image Figure 9. Deep Vein Thrombosis Image Figure 10. Atrial Fibrillation Image Figure 11. Other Image Figure 12. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Direct Oral Anticoagulants (DOACs) Revenue (2021-2032) & (US$ Million) Figure 14. Global Direct Oral Anticoagulants (DOACs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2032) Figure 17. Global Direct Oral Anticoagulants (DOACs) Sales (2021-2032) & (K Units) Figure 18. Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Direct Oral Anticoagulants (DOACs) Sales YoY (2021-2032) & (K Units) Figure 21. Europe Direct Oral Anticoagulants (DOACs) Sales YoY (2021-2032) & (K Units) Figure 22. China Direct Oral Anticoagulants (DOACs) Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Direct Oral Anticoagulants (DOACs) Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales YoY (2021-2032) & (K Units) Figure 25. Global Direct Oral Anticoagulants (DOACs) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Direct Oral Anticoagulants (DOACs) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2032) Figure 31. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2032) Figure 34. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2032) Figure 37. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2032) Figure 40. North America Direct Oral Anticoagulants (DOACs) Revenue Share by Type (2021-2032) Figure 41. North America Direct Oral Anticoagulants (DOACs) Sales Share by Type (2021-2032) Figure 42. North America Direct Oral Anticoagulants (DOACs) Revenue Share by Application (2021-2032) Figure 43. North America Direct Oral Anticoagulants (DOACs) Sales Share by Application (2021-2032) Figure 44. North America Direct Oral Anticoagulants (DOACs) Revenue Share by Country (2021-2032) Figure 45. North America Direct Oral Anticoagulants (DOACs) Sales Share by Country (2021-2032) Figure 46. Europe Direct Oral Anticoagulants (DOACs) Revenue Share by Type (2021-2032) Figure 47. Europe Direct Oral Anticoagulants (DOACs) Sales Share by Type (2021-2032) Figure 48. Europe Direct Oral Anticoagulants (DOACs) Revenue Share by Application (2021-2032) Figure 49. Europe Direct Oral Anticoagulants (DOACs) Sales Share by Application (2021-2032) Figure 50. Europe Direct Oral Anticoagulants (DOACs) Revenue Share by Country (2021-2032) Figure 51. Europe Direct Oral Anticoagulants (DOACs) Sales Share by Country (2021-2032) Figure 52. China Direct Oral Anticoagulants (DOACs) Revenue Share by Type (2021-2032) Figure 53. China Direct Oral Anticoagulants (DOACs) Sales Share by Type (2021-2032) Figure 54. China Direct Oral Anticoagulants (DOACs) Revenue Share by Application (2021-2032) Figure 55. China Direct Oral Anticoagulants (DOACs) Sales Share by Application (2021-2032) Figure 56. Asia Direct Oral Anticoagulants (DOACs) Revenue Share by Type (2021-2032) Figure 57. Asia Direct Oral Anticoagulants (DOACs) Sales Share by Type (2021-2032) Figure 58. Asia Direct Oral Anticoagulants (DOACs) Revenue Share by Application (2021-2032) Figure 59. Asia Direct Oral Anticoagulants (DOACs) Sales Share by Application (2021-2032) Figure 60. Asia Direct Oral Anticoagulants (DOACs) Revenue Share by Country (2021-2032) Figure 61. Asia Direct Oral Anticoagulants (DOACs) Sales Share by Country (2021-2032) Figure 62. SAMEA Direct Oral Anticoagulants (DOACs) Revenue Share by Type (2021-2032) Figure 63. SAMEA Direct Oral Anticoagulants (DOACs) Sales Share by Type (2021-2032) Figure 64. SAMEA Direct Oral Anticoagulants (DOACs) Revenue Share by Application (2021-2032) Figure 65. SAMEA Direct Oral Anticoagulants (DOACs) Sales Share by Application (2021-2032) Figure 66. SAMEA Direct Oral Anticoagulants (DOACs) Revenue Share by Country (2021-2032) Figure 67. SAMEA Direct Oral Anticoagulants (DOACs) Sales Share by Country (2021-2032) Figure 68. Direct Oral Anticoagulants (DOACs) Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Direct Oral Anticoagulants (DOACs) Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Factor Xa Inhibitors
  • Direct Thrombin Inhibitors (DTIs)
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • Teva Pharmaceutical
  • Viatris
  • Bayer
  • Pfizer
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Direct Oral Anticoagulants (DOACs) Market by Type
  3. 1.2.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Factor Xa Inhibitors
  5. 1.2.3 Direct Thrombin Inhibitors (DTIs)
  6. 1.3 Direct Oral Anticoagulants (DOACs) Market by Application
  7. 1.3.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pulmonary Embolism
  9. 1.3.3 Deep Vein Thrombosis
  10. 1.3.4 Atrial Fibrillation
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Direct Oral Anticoagulants (DOACs) Market Dynamics
  1. 2.1 Direct Oral Anticoagulants (DOACs) Industry Trends
  2. 2.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
  3. 2.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
  4. 2.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Direct Oral Anticoagulants (DOACs) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region
  3. 3.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026)
  5. 3.2.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2027-2032)
  6. 3.2.4 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Direct Oral Anticoagulants (DOACs) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Direct Oral Anticoagulants (DOACs) Sales by Region
  9. 3.4.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026)
  11. 3.4.3 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2027-2032)
  12. 3.4.4 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers
  2. 4.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Direct Oral Anticoagulants (DOACs) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers
  6. 4.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Direct Oral Anticoagulants (DOACs) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Direct Oral Anticoagulants (DOACs) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Direct Oral Anticoagulants (DOACs) Manufacturers, Product Type & Application
  13. 4.7 Global Direct Oral Anticoagulants (DOACs) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Direct Oral Anticoagulants (DOACs) Market CR5 and HHI
  16. 4.8.2 2025 Direct Oral Anticoagulants (DOACs) Tier 1, Tier 2, and Tier 3
5 Direct Oral Anticoagulants (DOACs) Market by Type
  1. 5.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type
  2. 5.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type
  6. 5.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Direct Oral Anticoagulants (DOACs) Price by Type
6 Direct Oral Anticoagulants (DOACs) Market by Application
  1. 6.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application
  2. 6.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application
  6. 6.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Direct Oral Anticoagulants (DOACs) Price by Application
7 Company Profiles
  1. 7.1 Accord Healthcare
  2. 7.1.1 Accord Healthcare Company Information
  3. 7.1.2 Accord Healthcare Business Overview
  4. 7.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
  6. 7.1.5 Accord Healthcare Recent Developments
  7. 7.2 Apotex
  8. 7.2.1 Apotex Company Information
  9. 7.2.2 Apotex Business Overview
  10. 7.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
  12. 7.2.5 Apotex Recent Developments
  13. 7.3 Boehringer Ingelheim
  14. 7.3.1 Boehringer Ingelheim Company Information
  15. 7.3.2 Boehringer Ingelheim Business Overview
  16. 7.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Recent Developments
  19. 7.4 Bristol Myers Squibb
  20. 7.4.1 Bristol Myers Squibb Company Information
  21. 7.4.2 Bristol Myers Squibb Business Overview
  22. 7.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
  24. 7.4.5 Bristol Myers Squibb Recent Developments
  25. 7.5 Daiichi Sankyo
  26. 7.5.1 Daiichi Sankyo Company Information
  27. 7.5.2 Daiichi Sankyo Business Overview
  28. 7.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
  30. 7.5.5 Daiichi Sankyo Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Janssen Pharmaceuticals
  38. 7.7.1 Janssen Pharmaceuticals Company Information
  39. 7.7.2 Janssen Pharmaceuticals Business Overview
  40. 7.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
  42. 7.7.5 Janssen Pharmaceuticals Recent Developments
  43. 7.8 Teva Pharmaceutical
  44. 7.8.1 Teva Pharmaceutical Company Information
  45. 7.8.2 Teva Pharmaceutical Business Overview
  46. 7.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
  48. 7.8.5 Teva Pharmaceutical Recent Developments
  49. 7.9 Viatris
  50. 7.9.1 Viatris Company Information
  51. 7.9.2 Viatris Business Overview
  52. 7.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
  54. 7.9.5 Viatris Recent Developments
  55. 7.10 Bayer
  56. 7.10.1 Bayer Company Information
  57. 7.10.2 Bayer Business Overview
  58. 7.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
  60. 7.10.5 Bayer Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Mylan
  68. 7.12.1 Mylan Company Information
  69. 7.12.2 Mylan Business Overview
  70. 7.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
  72. 7.12.5 Mylan Recent Developments
  73. 7.13 Sandoz
  74. 7.13.1 Sandoz Company Information
  75. 7.13.2 Sandoz Business Overview
  76. 7.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
  78. 7.13.5 Sandoz Recent Developments
8 North America
  1. 8.1 North America Direct Oral Anticoagulants (DOACs) Market Size by Type
  2. 8.1.1 North America Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
  3. 8.1.2 North America Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
  4. 8.1.3 North America Direct Oral Anticoagulants (DOACs) Price by Type (2021-2032)
  5. 8.2 North America Direct Oral Anticoagulants (DOACs) Market Size by Application
  6. 8.2.1 North America Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
  7. 8.2.2 North America Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
  8. 8.2.3 North America Direct Oral Anticoagulants (DOACs) Price by Application (2021-2032)
  9. 8.3 North America Direct Oral Anticoagulants (DOACs) Market Size by Country
  10. 8.3.1 North America Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Direct Oral Anticoagulants (DOACs) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Direct Oral Anticoagulants (DOACs) Market Size by Type
  2. 9.1.1 Europe Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
  4. 9.1.3 Europe Direct Oral Anticoagulants (DOACs) Price by Type (2021-2032)
  5. 9.2 Europe Direct Oral Anticoagulants (DOACs) Market Size by Application
  6. 9.2.1 Europe Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
  8. 9.2.3 Europe Direct Oral Anticoagulants (DOACs) Price by Application (2021-2032)
  9. 9.3 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country
  10. 9.3.1 Europe Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Direct Oral Anticoagulants (DOACs) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Direct Oral Anticoagulants (DOACs) Market Size by Type
  2. 10.1.1 China Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
  3. 10.1.2 China Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
  4. 10.1.3 China Direct Oral Anticoagulants (DOACs) Price by Type (2021-2032)
  5. 10.2 China Direct Oral Anticoagulants (DOACs) Market Size by Application
  6. 10.2.1 China Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
  7. 10.2.2 China Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
  8. 10.2.3 China Direct Oral Anticoagulants (DOACs) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Direct Oral Anticoagulants (DOACs) Market Size by Type
  2. 11.1.1 Asia Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
  4. 11.1.3 Asia Direct Oral Anticoagulants (DOACs) Price by Type (2021-2032)
  5. 11.2 Asia Direct Oral Anticoagulants (DOACs) Market Size by Application
  6. 11.2.1 Asia Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
  8. 11.2.3 Asia Direct Oral Anticoagulants (DOACs) Price by Application (2021-2032)
  9. 11.3 Asia Direct Oral Anticoagulants (DOACs) Market Size by Country
  10. 11.3.1 Asia Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Direct Oral Anticoagulants (DOACs) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Direct Oral Anticoagulants (DOACs) Market Size by Type
  2. 12.1.1 SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Direct Oral Anticoagulants (DOACs) Price by Type (2021-2032)
  5. 12.2 SAMEA Direct Oral Anticoagulants (DOACs) Market Size by Application
  6. 12.2.1 SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Direct Oral Anticoagulants (DOACs) Price by Application (2021-2032)
  9. 12.3 SAMEA Direct Oral Anticoagulants (DOACs) Market Size by Country
  10. 12.3.1 SAMEA Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Direct Oral Anticoagulants (DOACs) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Direct Oral Anticoagulants (DOACs) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
  2. 13.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Direct Oral Anticoagulants (DOACs) Production Mode & Process
  6. 13.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Direct Oral Anticoagulants (DOACs) Distributors
  9. 13.2.3 Direct Oral Anticoagulants (DOACs) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst